Clinical trial NCT05451381: Vasopressor Requirements Depends on Sedation Strategy
Official title: Vasopressor Requirements During Dexmedetomidine Sedation vs Propofol vs Their Combination (Dexmedetomidine and Propofol) Sedation in Patients After Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sedative Adverse Reaction
Sedation Complication
Hemodynamic Instability
Agitation on Recovery From Sedation
Respiratory Complication
Lead sponsor: Anesthesia Research Group UA
Sponsor class: OTHER
First posted: 2022-07-11
Enrollment: 356
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Most of the patients after cardiac surgery need sedation in the iCU. Sedation strategy could impact the incidence of vasopressor use.

Detailed description: Sedating a patient is a complex process, especially after heart surgery. Sedation has a negative hemodynamic effect. This leads to a decrease in blood pressure and increases the frequency and dose of vasopressors used. The choice of drug for sedation may have an impact on reducing the frequency of use of vasopressor therapy. The goal of the research is compare three strategies: propofol ( sedative agent), dexmedetomidine ( selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative effect) and their combination for sedation after cardiac surgery.

Eligibility criteria: Inclusion Criteria:

* Multi vascular lesions of the coronary arteries according to coronary angiography;
* Heart valve damage was confirmed by heart ultrasound, which is subject to surgical correction (aortic stenosis of III degree with a gradient on the aortic valve of more than 42 mmHg, aortic insufficiency III, mitral valve stenosis II-III, mitral regurgitation II-III)
* Age of patients from 18-80 years;
* Patient consent to participate in the study;
* Women who have a negative pregnancy test and use effective contraception throughout the study and for 3 weeks after its completion, or women who are unable to have children (women who have undergone a hysterectomy (removal of the uterus) or tubal ligation, women with a clinical diagnosis of infertility) or are menopausal for more than 1 year (absence of menstruation for at least 12 months). Adequate methods of contraception include: surgical sterilization, double barrier method of contraception, local contraception;

Exclusion Criteria:

* Refusal to participate;
* Hypersensitivity to propofol, dexmedetomidine;
* Prolonged mechanical ventilation in case of surgical complications (bleeding, inadequate perfusion of the myocardium);
* Occurred ischemic stroke;
* History of the ischemic stroke;
* History of the neurodegenerative diseases;
* History of the mental disorders;
* Use of neuroleptics, antidepressants for the last 5 years;
* History of the cardiac surgery in the past;
* Patients with chronic pulmonary disease (GOLD 3-4)
* Patients with asthma (moderate or severe),
* Participation in any other clinical trial;
* Gastric or duodenal ulcer with risk of bleeding;
* Chronic renal failure (ClCr less than 50 ml / h)
* Acute renal failure that occurred during surgery (ClCr less than 50 ml / h, or a decrease in the rate of diuresis to 0.1 ml / h in the first 4 hours after surgery and does not respond to diuretic therapy)
* Chronic hepatic insufficiency if there are laboratory signs of hypo coagulation without the use of anticoagulant therapy (INR\> 1.5)
* If the patient has not stopped taking anticoagulants or antiplatelet agents in the preoperative period: warfarin 5 days before surgery, clopidogrel 5-7 days before surgery, xarelto / pradaxa 3 days before surgery),
* History of the hematological disease;
* Alcohol abuse in the anamnesis (3-4 times a week).
* Condition after chemotherapy;
* Pregnancy, lactation.

Primary outcomes:
measure: vasopressor requirements
timeFrame: every hour during sedation(up to 12 hours)
measure: dose of norepinephrine
timeFrame: every hour during sedation (up to 12 hours)
Secondary outcomes:
measure: Length of stay in the ICU
timeFrame: before discharging from ICU to the ward ( up to 3 days)
Other outcomes:
Locations:
city: Kyiv
country: Ukraine
facility: Cardiosurgery departments with intensive care block
Study officials:
affiliation: Chief of the anesthesia department
name: Yelyzaveta Plechysta, MD
role: PRINCIPAL_INVESTIGATOR
References: